Microdialysis for pharmacokinetic-pharmacodynamic studies

被引:2
|
作者
Yu, W. [1 ]
Cheng, Q. [1 ]
Feng, J. [1 ]
Li, F. [1 ]
机构
[1] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Dept Pharmaceut, Hangzhou 310053, Peoples R China
来源
PHARMAZIE | 2007年 / 62卷 / 12期
关键词
D O I
10.1691/ph.2007.12.7049
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Microdialysis (MD) has become one of the major tools to sample endogenous and exogenous substances in extracellular spaces. It is more suitable for pharmacokinetic-pharmacodynamic (PK-PD) studies than other techniques. This review aims to give an overview of MID for PK-PD (MD/PK-PD) studies, including PK-PD studies, three aspects (principles, recovery, advantages) of MD/PK-PD, and application examples of MD/PK-PD organized by types of drugs and information collected. It can be concluded that MID offers an unique opportunity, to study simultaneously pharmacokinetic (PK) behavior of a drug and its effect on the extracellular levels of endogenous compounds, which may facilitate proof-of-concept demonstrations for target modulation, enhance the rational selection of an optimal drug dose and schedule. In addition, MD/PK-PD can also minimize uncertainties associated with predicting drug safety and efficacy, reduce the high levels of drug attrition during development, accelerate drug approval, and decrease the overall costs of drug development.
引用
收藏
页码:883 / 891
页数:9
相关论文
共 50 条
  • [31] Pharmacokinetic-pharmacodynamic modeling of anticancer drug
    Park, IS
    Ahn, MR
    Suh, SK
    Choi, HS
    Sohn, SJ
    Kuh, HJ
    Yang, JS
    Yoo, TM
    DRUG METABOLISM REVIEWS, 2003, 35 : 28 - 28
  • [32] A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
    Ari Brekkan
    Luis Lopez-Lazaro
    Gunnar Yngman
    Elodie L. Plan
    Chayan Acharya
    Andrew C. Hooker
    Suresh Kankanwadi
    Mats O. Karlsson
    The AAPS Journal, 20
  • [33] Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
    Nielsen, Elisabet I.
    Friberg, Lena E.
    PHARMACOLOGICAL REVIEWS, 2013, 65 (03) : 1053 - 1090
  • [34] Grounds for the integration of pharmacokinetic-pharmacodynamic data
    Barbanoj, MJ
    Salazar, G
    Morte, A
    Antonijoan, RM
    Gich, I
    Jane, F
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1996, 18 : 43 - 45
  • [35] SEMIPARAMETRIC APPROACH TO PHARMACOKINETIC-PHARMACODYNAMIC DATA
    VEROTTA, D
    BEAL, SL
    SHEINER, LB
    AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (04): : R1005 - R1010
  • [36] PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS OF IMIDAZOLIDINEDIONE DERIVATIVES
    Saunders, David
    Kozar, Michael
    Victor, Melendez
    Li, Qiqui
    Teja-Isavadharm, Paktiya
    Montip, Gettayacamin
    O'Neill, Michael
    Ohrt, Colin
    Magill, Alan
    Lin, Ai J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 174 - 174
  • [37] Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling
    Colburn, WA
    Lee, JW
    CLINICAL PHARMACOKINETICS, 2003, 42 (12) : 997 - 1022
  • [38] Pharmacokinetic-pharmacodynamic models for inhaled anaesthetics
    Kreuer, S.
    Bruhn, J.
    Wilhelm, W.
    Bouillon, T.
    ANAESTHESIST, 2007, 56 (06): : 538 - 556
  • [39] Population pharmacokinetic-pharmacodynamic analysis of givinostat
    Fiorentini, Francesco
    Germani, Massimiliano
    Del Bene, Francesca
    Pellizzoni, Cinzia
    Cazzaniga, Sara
    Rocchetti, Maurizio
    Bettica, Paolo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (04) : 229 - 238
  • [40] Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf
    Aliabadi, FS
    Lees, P
    RESEARCH IN VETERINARY SCIENCE, 2003, 74 (03) : 247 - 259